The FDA has expanded the indication for Fiasp (insulin aspart injection; Novo Nordisk) 100 Units/mL to include use in insulin infusion pumps to improve glycemic control in adults with type 1 or type 2 ...
The expanded approval was based on data from the phase 3 PRONTO-PUMP-2 trial which evaluated Lyumjev vs Humalog for use in insulin pump therapy in 432 adults with type 1 diabetes. The Food and Drug ...
The FDA expanded the indication for insulin aspart injection 100 U/mL to include use in insulin infusion pumps for the improvement of glycemic response in adults with type 1 and type 2 diabetes, ...
The tubing used to subcutaneously deliver insulin from a Tandem Diabetes Care pump is among the latest devices to land in the FDA’s hot seat. Unomedical A/S began a recall of some of its VariSoft ...
With the prevalence of diabetes quadrupling in recent decades and currently impacting more than 500 million people in the world, it is no surprise that the technology for insulin delivery has also ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A follow-on therapy to insulin aspart was shown to be ...
Every time Vanessa publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...
Pump vs control sites had greater vessel density, fibrosis, fibrinogen, and inflammation including eosinophils, insulin-like-growth factor-1 (IGF-1), and transforming growth factor (TGF) β-3, as well ...
Skin reactions at insulin pump infusion sites are common among people with type 1 diabetes who use the devices and can lead to delivery failure, new research suggests. Insulin pump use is increasingly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback